ageLOC TFEU age OC TF U

Transcription

age OC TF U
ageLOC TFEU
A novel, proprietary formulation incorporating Nu A
novel, proprietary formulation incorporating Nu
Skin’s ageLOC technology with TFEU and ETHOCYN. Resulting in a unique and extraordinary topical skin g
q
y p
care product that specifically modulates (up regulates g
)
g
p
and down regulates) the genes responsible for the firm, resilient skin of youth.
Chantal Burnison
Chantal
Burnison
Biochemist Medically and scientifically published inventor
Chantal Burnison, Inventor
ETHOCYN Statement
A Clinically Proven Topical Bid Regimen Safe
A Clinically Proven, Topical, Bid Regimen, Safe, Target Tissue,
Non‐Steroidal Cosmetic Ingredient.
g
®
Structure
The ETHOCYN Molecule
Mechanism of Action Safety
y
Efficacy
y
•
Small (mwt 266), lipophilic compound , 8 stereo‐isomers’ racemate structure
•
Proven (IND issued by FDA) to be a safe, topical, non‐steroidal, target tissue, DHT receptor specific anti androgen (AA) • Penetrates to dermis into fibroblast cells via passive diffusion; confirmed in C14
and H3 trans dermal penetration studies: in vitro fibroblast assay., animal models for AA and clinical pharmacokinetic
models for AA and clinical pharmacokinetic.
•
Competitive DHT‐DHT receptor specific blocker
• 100% metabolized to a non AA within the skin dermis. No systemic absorption. C14 studies: in vitro, animal and clinical.
CV at www.chantalburnison.com
Presentation Contents
Presentation Contents
• Research and Development of Ethocyn® Molecule
p
y
• The $20mm Safety and Efficacy Preclinical Profiles and Mechanism of y
Action of Ethocyn® • Results of Medically Published Ethocyn® Clinical Trials
o UCLA Medical Center
o Univerity Shanghai Medical Center
o Dr. Jeffrey Hoefflin M.D.,F.A.C.S.,F.I.C.S.
• Ethocyn® and ageLOC TFEU for Firmer, Smoother, More Beautiful Skin
How Ethocyn
How Ethocyn® Works
Works
Unique cosmetic ingredient
g
in ageLOC
g
TFEU
19 years and $20million+ in research and
development. A topical, safe and
efficacious non steroidal anti-androgen.
that penetrates to the dermis
causing fibroblast cell to make elastin
Research and development of Ethocyn® molecule
at 20 year old youth levels.
Cellular Physiology of th DHT R
the DHT Receptor ‐
t
DHT Bi di
DHT Binding
• All Individuals are born with DHT receptors in their fibroblast cells
• We are genetically predisposed to inheriting the quantity of DHT receptors
• Additionally, as we age, the number of DHT receptors increase. Feedback
mechanism on DHT binding inducing more DHT receptors to be made by
cells.
cells
• Ethocyn competitively blocks intracellular DHT- DHT receptor binding
• Net result is an increase production of elastin by fibroblast cell in the
presence of Ethocyn
Ethocyn
Ethocyn® World Testing Centers
World Testing Centers
Works on:
• all skin ethnicities
• male and female
• > than 25 years of age
th 25
f
Patents Issued/Pending Around the World
Patents Issued/Pending Around the World
Patents
•
•
•
Composition of matter
Process
Use
Trade Secrets
•
•
•
•
Isomeric composition
Stereo specific synthesis
Exo‐ and endo‐ ratio studies
IND (Investigative New Drug) submissions
IND (Investigative New Drug) submissions and approvals
Trademarks
•
Ethocyn®
Ethocyn® Scientific & Medical Publications
Physician Information Brochure Summarizing ETHOCYN
Preclinical and Clinical Studies
md.com
The Ethocyn®Ingredient in ageLOC TFEU
•
•
•
•
•
•
Over $20 million and over 19 years of preclinical research and d l
t
development
Small Mwt. 266, lipophilic molecule
Non‐steroidal target tissue DHT receptor
tissue DHT‐receptor blocker
Passive diffusion to dermis (C14) transdermal
p
penetration studies
Safe (44 studies; 5 species) Efficacious DHT receptor blocker (competitive i hibi i ) M h i
inhibition) Mechanism of f
Action.
Ethocyn® Chantal Burnison, Inventor
ageLOC TFEU with Ethocyn® is Unique, Safe and g
y
q
Clinically Efficacious
• No other cosmetic ingredient in the world treats skin aging (skin laxity and wrinkling) in this important way that Ethocyn does
• Ethocyn® is a proven safe and efficacious, small mwt. non steroidal anti androgen
• TFEU ageLOC: a unique and extraordinary cosmetic formulation that has g
q
y
optimally combined Ethocyn® at its clinically proven MTD (maximum therapeutic dose) with extraordinary ageLOC researched moisturizers, antioxidants, anti‐inflammatory, mmp inhibiting, and collagen boosting ingredients.
• Ethocyn® is a unique, patented firming ingredient • Ethocyn® firms lax, wrinkled skin by increasing important skin elastin fibers y
,
y
g p
content (P <0.001)
• Elastin fibers are the skin’s “rubber bands”
It is important to have young skin levels of elastin fibers •The skin is comprised of collagen and elastin fibers synthesized by dermal fibroblast cells.
• Collagen fibers are the structural fibers of the skin. They do not stretch well.
C ll
fib
th t t l fib
f th ki Th d
t t t h ll
• Elastin fibers are the important “youth protein” fibers of skin. They give skin “snap back” elasticity.
• Young skin is abundant in elastin fibers. As we age elastin fiber content decreases. • Our skin’s elastin fibers are what give skin its retraction and snap. • Elastin fibers are concluded by expert Skin Phyisiologists to be the skins important ” YOUTH PROTEIN” .
Recognized Causes of Skin Aging
• Mechanical Aging M h i lA i
• Extrinsic Aging
Extrinsic Aging
• Intrinsic Aging
Intrinsic Aging
Old Skin
Old Ski
Young Skin
Y
Ski
Medical Text Book
Peter T. Pugliese, M.D.
School of Medicine at University of Pennsylvania
School
of Medicine at University of Pennsylvania
B’Nai Brith Americanism Award
Maison De Navarre Gold Medal Award
y
gy
American Academy of Dermatology member
•Authored >60 scientific papers
•Given >100 scientific mtg. presentations
•Contributed >10 chapters to scientific texts
•Published 4 books
The Single Most Important Cause…. The Single Most Important Cause….
“The single most important cause of age related wrinkles is
the loss of skin elastin fibers, Everyone, whether female or
male will begin to lose skin elastin fibers at age 25.
Elastin fibers are the restorative force on the skin.”
Peter
T Pugliese M D
Peter T. Pugliese M.D.
Internationally acclaimed author of the dermatology textbooks:
Physiology of Skin II and Advanced Professional Skin Care Chantal Burnison, Inventor
Ethocyn® and Its Mechanism of Action
Blocks dermal fibroblasts’
intracellular DHT binding: the published known cause of what signals fibroblasts skin cells, between 25 30 years of age
between 25‐30 years of age (depending on genetic predisposition) in both males and
predisposition) in both males and females, to stop producing elastin–
the important youth‐rendering skin’s rubber bands–that we have when we are young. Chantal Burnison, Inventor
Intrinsic Aging and Loss of Skin Elastin Fibers
• Both men and women are born with DHT receptors in their fibroblast cells
• We are genetically predisposed to inheriting the amount, or quantity, of DHT receptors that we possess in the different DHT t
t i i
ll f
b di
receptor containing cells of our bodies
• After 25‐35 years of age, no matter what our genetic make‐up, we will have more DHT receptors than anti‐androgens. Biofeedback mechanism activated at puberty. • We need to topically apply Ethocyn® to the skin 2x per day to assure DHT transcription as occurs in youth. Chantal Burnison, Inventor
Ethocyn® Clinical Trials Deliver Efficacy Profile at p<0.001
<0 001
What can one expect to experience and see using Ethocyn® p
p
g
y ?
•U.C.L.A. •University of Shanghai •Dermatologist Trials World ide to clinicall
•Dermatologist Trials Worldwide to clinically
• identify Ethocyn’s MTD •Plastic Surgeon Trials: Alone and
in combination with Fraxel Laser. Started Analyzing Ethocyn’s and elastin’s importance
and effect on wound healing.
g
Ethocyn’s Anti androgen efficacy established in
Earlier pharma trials for therapeutic indications of Acne, Hirsuitism, Alopecia, Keloids
Ethocyn
Ethocyn® Clinical Efficacy
Clinical Efficacy
Ethocyn® A clinically proven topical efficacious target tissue
A clinically proven, topical, efficacious target tissue, non‐steroidal cosmetic ingredient.
p<0 001
p<0.001
UCLA Dept. of Dermatology Clinical Trials
“Only Ethocyn®
“O l E h
® can give your skin the elastin fiber content of 20 year old i
ki h l i fib
f 20
ld
skin”
Clinical Trials
• Conducted by Dr. Richard Strick,M.D. Clinical Professor of Dermatology at U.C.L.A.
Professor of Dermatology at U.C.L.A. •Protocols reviewed and approved by
USA FDA • Presented Ethocyn® Clinical Trials’ research at the American Academy of Dermatology Medical Conference and numerous other medical forums. Chantal Burnison, Inventor
Ethocyn® Efficacy: University Medical Center’s Phase II Ethocyn
Ethocyn® Clinical Trials
Clinical Trials
• 2mm Punch biopsies --actual skin -were taken from each subject ; slides
randomized-thereby hiding identity of
Subjects and time sequence.
• Quantitative computer image analysis
of biopsies were conducted at Baseline,
1,2,3,4 and 6 months to assure
accuracy and statistically significant
results (p<0.001)
• Biopsy analyses: 250+ patients, male
and female;; 25-77 yyrs of age;
g ; different
ethnicities.
Double blind, punch biopsies conducted on hundreds of Subjects (25‐77 years of age; male and female) at independent university medical centers confirm (p <0 001)
male and female) at independent university medical centers confirm (p <0.001) Ethocyn® increases your skin’s important elastin fiber content to the youthful levels of 20 year old individuals. Study’ Control Group : was 18‐25 year olds, males and females.
p
g
Clinical Implications of Decreasing Skin Elastin
As tissue elastin levels decrease in quantity and quality with age:
Skin becomes less elastic
S
Skin loses it’s firmness and starts to sags
oses t s
ess a d sta ts to sags
Development of wrinkles & rhytids
Ethocyn® Clinical Trials’ Efficacy Results
Percent Increase in Elastin
Content
180
160
140
120
100
80
60
40
20
0
baseline
1 month
2 month
3 month
Percent Increase In Elastin Content
Breaking the Code at U.C.L.A. Ethocyn® Clinical Trials
Ethocyn®
Ethocyn® Topical BID application of Ethocyn® ™ by patients aged 40‐77 years of age restores elastin production to levels normally obtained in youth (ages 18‐25). The mean level of elastic tissue in Ethocyn® ™ treated individuals increased by 100% (in some patients over 500%) (P<0.001). Every individual, male and female subject, had shown improvement and had smoother, tighter and less wrinkled skin.
American Academy of Dermatology Medical Conference, San Francisco, California
Richard Strick, M.D.
Diplomat of American Academy of Dermatology
Clinical Professor of Dermatology U C L A School of Medicine
Clinical Professor of Dermatology, U.C.L.A. School of Medicine
Ethocyn® and ageLOC TFEU MTD and ADJUNCT TREATMENT CLINICAL TRIALS
MTD and ADJUNCT TREATMENT CLINICAL TRIALS
Jeffrey D. Hoefflin, M.D., F.A.C.S, F.I.C.S.
•
•
•
•
•
•
•
F ll t i d G
l
l ti
Fully trained General surgeon, plastic surgeon
Dual Board Certified Surgeon
Diplomate, The American Board of Plastic Surgery
Fellow The American College of Surgeons
Fellow, The American College of Surgeons
Fellow, The International College of Surgeons
Fellow, Bay Surgical Society
Member, Los Angeles Society of Plastic Surgeons
Member, Los Angeles Society of Plastic Surgeons
Elastin’s Role In Wound Healing
• Mechanism of Aging: Intrinsic and Extrinsic factors involved
• Intrinsic skin aging associated with delayed wound healing
• Decrease in: GF’s; TIMP; collagen; elastin and dermal thickness
• Elastin fibers: Decrease in quantity and increase in fiber size
• Observation: Reduced skin elasticity
Ob
ti
R d d ki l ti it
• Clinical : Dryness, looseness, thinning, wrinkling
• Ethocyn Unique solution to improve Elastin quantity and quality
Fractionated Laser Resurfacing
• Next generation of ‘safe’
safe and efficient’
efficient lasers
• Less downtime compared to traditional lasers
• Can be performed in office setting
• Five to seven day healing process
• Indications: pigment dyschromias, hyperpigmentation,
•melasma, all levels of rhytids.
Laser Resurfacing Study Protocols Dr Jeffrey Hoefflin M D F A C S F I C S
Dr. Jeffrey Hoefflin M.D., F.A.C.S., F.I.C.S
• Ethocyn® and Laser Resurfacing Study
Ethocyn® and Laser Resurfacing Study
• Fraxel Fractionated CO2 – Full Face Laser Skin Resurfacing
• Topical BID application of Ethocyn® ®
• Patient age range (aged 28
Patient age range (aged 28‐62
62 years) Mean elastic tissue level in years) Mean elastic tissue level in
treated side of individuals increased 100% (p<0.001). Every individual (male and female) showed improvement on
• Every individual (male and female) showed improvement on Ethocyn TFEU side. Had smoother, tighter and less wrinkled skin.
Dr. Hoefflin Ethocyn® + Laser Study
• 8 weeks Clinical Trials’ Study; 20 Patients: Aged 28‐62 yrs.
• Ethocyn® application BID on one side and placebo on other side of each individual in the Study. Double Blind, Placebo Controlled
• Laser Procedure after 45 days of Ethocyn® and Palcebo BID (2x per L
P
d
ft 45 d
f Eth
® d P l b BID (2
day) regimen
• Interrupt Ethocyn® application 5 days (post surgically)
p
y
pp
y (p
g
y)
• Resume Ethocyn® application
• Physician and patients subject to analysis
• Conclusion, Patients Using Ethocyn® Remarked More Younger, Firmer Skin on Ethocyn® Treated Side
Ethocyn® and Laser Resurfacing Patient Example
i
l
Ethocyn® Optimizes Laser Results
• Topical BID application of Ethocyn
p
pp
y ®
• Patients (aged 28‐62 years) – elastin on treated side restored to youth levels (ages 18‐25)
youth levels (ages 18
25)
• Mean elastic tissue level of skin on treated side of individuals increased 100% (p<0 001)
increased 100% (p<0.001). • Every individual (male and female) showed improvement and had smoother tighter and less wrinkled skin
had smoother, tighter and less wrinkled skin.
Ethocyn Clinical Trial’ Publication
American Society of Plastic Surgeons Medical Conference
Ethocyn® Medical Conferences and Publications 2011‐2012
2011 2012
American Society of Plastic & Reconstructive
Surgery
:Oct 2011 - Volume 128 - Issue 4S - p 110
doi: 10.1097/01.prs.0000406341.77839.a2
American Society of Plastic Surgery- Poster;
Sept 23-27,
3 , 2011
0 in Denver,
e e , Co
Colorado.
o ado
Qara Raymi Dermatology Conference,
Lima, Peru
August 26-29, 2011
SUMMARY: Advantages of ageLOC TFEU with Ethocyn Feature Ingredient
• Ethocyn® ingredient formulated at its MTD clinically efficacious dose (Numerous Clinical Trials Dose Response Studies conducted: 15% 10%
(Numerous Clinical Trials Dose Response Studies conducted: 15%, 10%, 5%, 0.5%, 0.25%, 0.0025%)
• Non‐phototoxic –unlike efficacious retinoids and numerous AHAs
• Hypoallergenic‐ RIPT clinical test panels confirm
• Non‐irritating – RIPT clinical test panels confirm
• Non‐fragrance‐
g
express formulation design. An anhydrous formulation
p
g
y
• Proprietary ageLOC TFEU formulation containing (at established efficacy doses) twelve researched anti‐inflammatory, elastin and collagen boosting ingredients with excellent mmp inhibitor and other important functional
ingredients, with excellent mmp inhibitor and other important functional ingredients
• Multi‐functional formulation simplifies your daily skin care regimen
How to Use ageLOC TFEU containing Ethocyn
g
g
y ® ETHOCYN® BID TOPICAL DERMAL APPLICATION : • Metabolizes in the body within 8 to 10 hours–therefore it y
should be applied TWICE DAILY, morning and evening, on clean skin and/or in combination with non‐lipid adhering (e g water soluble) products
(e.g. water soluble) products.
Ethocyn® and Sun Exposure
• NON‐PHOTO TOXIC – You CAN go in the sun without worrying about redness or swelling.
In CONJUNCTION WITH SUNSCREENS and
In CONJUNCTION WITH SUNSCREENS and BLOCKS: protect your skin from the sun because the sun causes elastin fibers in the skin to become hard and non‐resilient; a condition known as elastosis.
FACT: ageLOC TFEU
ageLOC TFEU containing Ethocyn Increases your skin’s ‘Rubber Bands’ (elastin fibers) to that of 20 year old skin . So USE TWICE A DAY y
for…
Firmer… Smoother… More Snap Back, B
Beautiful Skin
if l Ski
Ethocyn® Announcements
“A
A major breakthrough in the fight major breakthrough in the fight
against skin aging.”
‐Dr. Bruce Hensel, Channel 4 News
Ethocyn® ’s importance previewed on USA television news stations when Dr. Richard Strick presented at AAD Medical Conference.
Ethocyn® gives skin the elastin fiber content of 20 year old skin.
“Eth
® i
ki th l ti fib
t t f 20
ld ki ”
–Dr. Richard Strick
UCLA Dermatology Professor
Numerous Television News Broadcasts
Covering Ethocyn® clinical trials’
i
h
® li i l i l ’ medical conference publications
di l
f
bli i
“Studies
Studies show this product works show this product works
differently from
others, and experts say it does work” “The
The compound actually
compound actually
restores elasticity to aging skin.”
‐NBC (Channel 4) Television News Report
“What’s in this little bottle could
turn back the hands of time”
‐KTLA (Channel 5) Television News Report
“The Fountain of Youth in a bottle” ‐Hard Copy Investigative News Report
Medical Directors of U.S. University Dermatology Departments state:
“Ethocyn® is the most effective cosmetic product available.” Interview of Dr. Tina Alster, Clinical Professor of Dermatology at Georgetown University School of Medicine.
Her patients include politicians, newscasters, models and lawyers.
p
p
,
,
y
Dr. Alster said, “To treat and prevent my own eye skin‐area wrinkles: I use a drop of Chantal Ethocyn® Serum every morning and evening around my eyes…I recommend Ethocyn® to all my patients.” Chantal Burnison, Inventor
Ethocyn® Users’ Testimonials
“I feel like Ethocyn® is actually repairing my skin.”
“It’s the perfect little magic drop.” “Within two weeks I saw a big difference.”
“The Ethocyn® changed my skin in a way
I’ve never seen before.” “The
The tightness in my skin came back,
I think everybody should know about
Ethocyn® .”
“The Ethocyn® essence is
easy to use and gave me great results.” Chantal Burnison, Inventor
“I feel younger, I feel like I look younger ” younger.
Ethocyn® Users’ Testimonials
“The lines have disappeared, I’m not feeling
uncomfortable any more.”
“Next to being a baby, this is the best
my skin has ever looked.”
Ethocyn® Treatment Products
Used everyday by men and women
Used everyday by men and women who care about skin health and beauty
who care about skin health and beauty
Karen Philips, a working American wife, decided to test Ethocyn® herself by using the product on only
half of her face, twice a day, for 120 days.
The results of her “half face test” are seen in this picture.
ageLOC TFEU & Ethocyn ageLOC TFEU & Ethocyn

ageLOC TFEU age OC TF U

Transcription

Similar documents

Write Your Heart Out…™

B2E-PHYSICIANS SCIENCE TRIFOLD ENG

Chantal and Alain Bertrand

25 عاما م لأ ال سمع يف 25 عاما م لأ ال سمع يف اخلفاء بعيدا عن النظر!! اخلف

Magazine Spread | 2016 PowerWomen

Jeffrey D. Hoefflin, MD, FACS, FICS

Famous scientists and their inventions